HSBC ups Ranbaxy to overweight on generic Lipitor announcement
MUMBAI (Reuters) - HSBC raised its rating on shares of Ranbaxy Laboratories Ltd (RANB.NS) to 'overweight' from 'underweight' after the Indian drugmaker said it would resume production of a generic version of cholesterol fighter Lipitor for sale in the United States.
HSBC added other factors behind its upgrade were share valuations after a recent correction, as well as the near-term catalysts such as the launch of additional generic drugs and the probability of a recovery in U.S. sales.
Ranbaxy shares were up 3.3 percent as of 9:34 a.m.
(Reporting by Abhishek Vishnoi; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- UPDATE 2-U.S. exits GM stake, taxpayers lose $10 billion
- UPDATE 1-Fannie Mae, Freddie Mac to hike mortgage guarantee fees
- China-Brazil satellite launch fails, likely fell back to Earth
- RPT-Record low temperature recorded in Antarctica -scientists
- SINGAPORE PRESS-Government tweaks executive condominium scheme - Business Times
This business of notes is livelihood for hundreds in Old Delhi, with vendors charging a fee of up to 20 percent to replace damaged banknotes. A mildly damaged 500 rupee note, for instance, can be exchanged for 480 rupees, while a bundle of crisp, new 10 rupee notes valued at 1,000 rupees is priced at 1,050 rupees. Full Article